All news

Spineway, specialized in the treatment of severe disorders of the spine, announces the publication of a scientific article in the renowned scientific journal Spine Deformity1 highlighting the benefits of the Mont-Blanc 3D+ technology for the treatment of adolescent idiopathic scoliosis.

Spineway’s Board of Directors, at a meeting held on 15 April 2020 chaired by Stéphane Le Roux, closed the 2019 annual accounts. The Group’s Statutory Auditors have audited these accounts and their reports are being prepared.

In keeping with its development strategy, Spineway wishes to be in a position to take advantage of any and all external-growth opportunities that could create value and new synergies. To this end, Spineway decided to launch a new subscription phase for Convertible Bonds with warrants.

The first half of this year was understandably affected by the health crisis caused by the worldwide Coronavirus pandemic, which led to the cancellation of all non-essential surgeries. During this unprecedented period, the Spineway group was fully committed to providing the best possible services to its direct clients in France and its international distribution partners. These efforts allowed the Group to keep its revenue for the second quarter at close to 30% of that of the previous year despite a very complicated international situation, resulting in half-year revenue of €1 432K as at 30 June 2020 (-45% compared with HY1 2019)

2019 was a particularly active year for the SPINEWAY group as it redeployed its activities in previously covered areas, completely reorganized its teams and renewed half its Executive Committee at the end of 2019. Spineway also strengthened its financial position thanks to a financing agreement with Negma Group1 in order to ensure organic growth and finance new development projects. The Group thus generated total revenue of €5 015K for 2019.

Spineway, specialized in innovative implants for the treatment of severe disorders of the spinal column (spine), announces its choice of TUV Rheinland as the notified body for the certification of its implant and instrument product lines. With the European regulations governing medical devices constantly changing and ever more stringent, Spineway thus ensures that it will be able to provide high-quality products consistently.

The Extraordinary and Ordinary General Meeting of Spineway’s shareholders that was held behind closed doors on 26 May 2020, at 2 p.m. at the Group’s registered office located at 7 allée Moulin Berger, 69130 Ecully, adopted all the resolutions submitted by over 90% except for resolution no. 10, which was dismissed unanimously at the Board of Directors’ recommendation. During this Meeting, the decision was approved to decrease the company’s share capital by absorbing losses and decreasing the par value of the shares.

Spineway’s Board of Directors, at a meeting held on 25 January 2021 chaired by Stéphane Le Roux, closed the 2020 annual accounts.